Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sabatolimab - Novartis Oncology

Drug Profile

Sabatolimab - Novartis Oncology

Alternative Names: AntiTIM-3 monoclonal antibody Novartis; MBG-453; NVP-MBG453

Latest Information Update: 31 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Vaccines
  • Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic myelomonocytic leukaemia
  • Phase I/II Myelofibrosis; Solid tumours
  • Phase I Myelodysplastic syndromes
  • No development reported Glioblastoma
  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 17 May 2024 Novartis terminates a phase-I trial in Myelodysplastic syndromes (Monotherapy, Combination therapy, Second-line therapy or greater) in Spain, South Korea, Italy, Israel, Australia, USA (SC) due to business reasons (NCT04810611)
  • 31 Dec 2023 Discontinued - Phase-II for Myelodysplastic syndromes (Second-line therapy or greater) in USA (IV)
  • 31 Dec 2023 Discontinued - Phase-I for Acute myeloid leukaemia (Combination therapy) in Singapore, Switzerland, Italy (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top